Since neuroblastoma demonstrates some potential for sensitivity to antimitotic approaches in the clinic such as AURKA inhibitors [39], this suggests further investigation is warranted for the molecular interactions between MYCN and mitosis, in particular those that represent potential vulnerabilities to new combination therapies [40,41]. The gene discussed is AURKA; the disease is neuroblastoma.